Postmus P E, Berendsen H H, van Zandwijk N, Splinter T A, Burghouts J T, Bakker W
Department of Pulmonary Diseases, State University, Groningen, The Netherlands.
Eur J Cancer Clin Oncol. 1987 Sep;23(9):1409-11. doi: 10.1016/0277-5379(87)90128-3.
In 37 patients with small cell lung cancer treatment with five cycles of cyclophosphamide, doxorubicin and etoposide (CDE), resulted in 23 complete (CR) and 14 partial responses (PR). Median response duration was 34 weeks. At relapse all patients were retreated with CDE. In 23 (62%) patients this gave a second response (6 CR, 17 PR). Factors influencing the occurrence of a second response were: 1. a CR after the first five cycles of CDE; 18 out of 23 CR patients responded again whereas only five of the 14 PR patients responded (P less than 0.01). 2. 15 out of 19 patients with a first response duration greater than 34 weeks reached a second response and in eight of the other 18 patients retreatment was successful (P less than 0.05). Reinduction at relapse, after short term chemotherapy and a treatment-free interval, with the induction regimen is an effective second line treatment in patients with an initial CR and a first response duration of greater than 34 weeks.
37例小细胞肺癌患者接受了五个周期的环磷酰胺、阿霉素和依托泊苷(CDE)治疗,结果有23例完全缓解(CR),14例部分缓解(PR)。中位缓解持续时间为34周。复发时所有患者均再次接受CDE治疗。23例(62%)患者出现了第二次缓解(6例CR,17例PR)。影响第二次缓解发生的因素有:1. 前五个周期CDE治疗后达到CR;23例CR患者中有18例再次缓解,而14例PR患者中只有5例缓解(P<0.01)。2. 首次缓解持续时间大于34周的19例患者中有15例达到第二次缓解,其他18例患者中有8例再次治疗成功(P<0.05)。对于初始为CR且首次缓解持续时间大于34周的患者,在短期化疗和无治疗间隔后复发时,采用诱导方案进行再诱导是一种有效的二线治疗方法。